Application of HV348 in preparation of product for distinguishing pneumonia and tuberculosis
Through exosomal proteomics research, biomarkers such as TLN1, APOH, and PSMD8 were identified to distinguish between lung cancer, tuberculosis and pneumonia, and solved the problem of insufficient diagnostic sensitivity and specificity in the prior art, achieving high efficiency, Non-invasive etiology identification.
Patent Information
- Application Number
- CN202410701440.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-31
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is insufficient in diagnosing and distinguishing the causes of pleural effusion, especially lung cancer, tuberculosis and pneumonia, and cannot be effectively differentiated. The existing methods have problems of high invasiveness and long diagnosis time.
Through quantitative proteomics research based on data independent acquisition (DIA), combined with OPLS-DA analysis, functional enrichment analysis and ROC analysis, exosomal proteins such as TLN1, APOH, PSMD8, SYWC were identified as biomarkers, and used to distinguish them from each other. Lung cancer, tuberculosis and pneumonia, and develop detection reagents, kits, microarrays or biochip products.
Accurate identification of lung cancer, tuberculosis and pneumonia is achieved, and a high sensitivity and specificity diagnostic tool is provided, which simplifies the diagnostic process, reduces invasiveness and improves diagnostic efficiency.
Smart Images

Figure CN118914557A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, and in particular relates to the application of HV348 in preparing products for distinguishing pneumonia from tuberculosis. Background Art
[0002] Pleural effusion (PE), also known as pleural effusion, occurs in the pleural cavity due to rapid filtration or slow reabsorption of fluid. The most common causes of PE are cancer, tuberculosis, pneumonia, and heart failure. Clinically, when diagnosing PE, it is essential to first determine the nature of the fluid. According to Light's criteria, if the pleural fluid has any of the following characteristics: i) pleural fluid total protein / serum protein>0.5; ii) pleural fluid LDH / serum LDH>0.6; iii) pleural fluid LDH>2 / 3 of the reference value on serum LDH, it can be judged as exudate; otherwise, it is offside. The sensitivity of Light's criteria for diagnosing exudates is 99% and the specificity is 98%. Subsequently, it is necessary to examine the cause of pleural effusion, such as exudative pleural effusion, which has important diagnostic value for further determining the cause of pleural effusion.
[0003] Pleural exudates are mainly caused by tumors, tuberculosis, pneumonia, connective tissue diseases, etc., while pleural effusions can be caused by any cause of heart failure, low protein blood levels, etc. Malignant pleural effusion (MPE) is the second most common cause of PE, accounting for about 15% of cancer patients. Among patients with lung cancer, up to 40% of patients will develop PE. When cancer causes PE, it often indicates that the patient's disease progresses or distant metastasis, with a poor prognosis and a median survival time of 3 to 12 months. Therefore, distinguishing between benign and malignant PE is crucial for the treatment and prognosis of patients. The pleural cavity is the second most common extrapulmonary infiltration site, and about 6.5-8.7% of patients with pulmonary tuberculosis develop tuberculous PE. In areas with a high incidence of tuberculosis, up to 30% of patients with pulmonary tuberculosis will develop tuberculous pleurisy. If diagnosis and treatment are delayed, it can lead to adhesive chylothorax or fibrothorax, seriously damaging the function of the affected lung. In addition, tuberculous pleurisy is a common complication of bacterial pneumonia, with an annual morbidity and mortality rate of 15%. Early diagnosis and treatment can prevent irreversible lung damage and reduce mortality.
[0004] Although various tools such as cytology, biochemical analysis, bacterial culture, and pleural biopsy can help clarify the cause of PE, they all have limitations. For example, according to different studies, the sensitivity of cytology for malignant pleural effusions ranges from 40% to 90%. In primary lung cancer, the sensitivity of pleural fluid cytology for lung adenocarcinoma (LUAD) is as high as 83.6%, followed by mesothelioma at 28.9%, and squamous cell carcinoma at only 24.2%. For the differential diagnosis of pleural effusions such as MPE, tuberculous pleural effusion (TPE), and pneumonic pleural effusion (PPE), tumor markers (CEA, SCC, CA199, CA125, CA153), adenosine deaminase (ADA), lactate dehydrogenase (LDH), high-sensitivity C-reactive protein (hs-CRP), and combined detection of LDH and ADA are used. However, the sensitivity and specificity of these methods are insufficient and cannot effectively identify the cause of pleural effusion. For tuberculous pleural effusion, pleural fluid culture and positive staining for acid-fast bacilli are the gold standard for diagnosis, but the culture time is long and the sensitivity is low, which is not conducive to the timely diagnosis of TPE. For PPE, the positive rate of pleural fluid culture is only 14%, even lower than the 24% of blood culture. Although next-generation sequencing can improve the sensitivity of pathogen monitoring in pleural fluid, it cannot effectively determine whether the causative pathogen is at work. Therefore, it is necessary to explore new and effective biomarkers to identify PE, especially exudative pleural effusion, without invasiveness.
[0005] In recent years, exosomes have become the focus of research due to their potential in diagnosis and treatment. Exosomes are components of extracellular vesicles with a diameter of 30-150nm, formed by endosomes produced by endocytosis and released by cells into the extracellular space. They have a lipid bilayer structure that effectively protects their contents from degradation by proteolytic enzymes present in the external environment. The long-term stability of exosomal proteins in the blood circulation makes them suitable as non-invasive biomarkers, and they can act as important mediators between cells, with important diagnostic and therapeutic potential. This makes exosomes a hot topic in recent research. Exosomes not only play an important role in regulating diseases such as tumorigenesis, tumor vascularization, immune escape, and changes in the tumor microenvironment, but have also been identified as the main component of PE, and its molecules are used as molecular markers for the diagnosis of malignant pleural effusions MPE and TPE. Exosomes are rich in RNA, such as miRNA, long non-coding RNA, DNA, proteins, lipids, metabolites, and small molecules. They are secreted by cells and transported to the circulatory system and extracellular fluid, where they transmit signal molecules to receptor cells, leading to changes in the structure and function of receptor cells. In addition, increasing evidence suggests that extracellular vesicles released by cancer cells may carry proteins that promote organ-specific metastasis. Exosomes are present in large quantities in pleural effusions, especially in malignant pleural effusions and tuberculous pleural effusions, and can be used as diagnostic biomarkers. Despite a large number of studies exploring exosomal DNA, mRNA, and noncoding RNA, the exosomal proteomics of PE has been largely overlooked. In 2004, Bard, MP, et al. found that the exosomal proteins of MPE were rich in different types of immunoglobulins and complement factors, antigen presentation molecules, cytoskeletal proteins, and signal transduction-related proteins, and proposed that these exosomal proteins could be used as immunotherapeutic drugs for MPE. Subsequently, Park JO, et al. used 1D SDS-PAGE and nano-LC-MS / MS to conduct an in-depth analysis of non-small cell lung cancer-related PE and identified 912 vesicle-associated proteins. By comparison with other malignancies, lung-enriched surface antigens and proteins associated with the epidermal growth factor receptor signaling pathway were identified as potential diagnostic markers for NSCLC. Summary of the invention
[0006] To further understand the exosomal proteomics of PE, our study collected a total of 47 PE samples, including 33 cases of lung cancer, 9 cases of tuberculosis, and 5 cases of pneumonia pleural effusion. Through quantitative proteomics research based on data independent acquisition (DIA), there were 109 differentially expressed proteins (DEPs) between the lung cancer group and the tuberculosis group, 109 differentially expressed proteins between the lung cancer group and the pneumonia group, and 49 differentially expressed proteins (DEPs) between the tuberculosis group and the pneumonia group. Through OPLS-DA analysis, functional enrichment analysis, receiver operating characteristic (ROC) analysis, and a series of validation and evaluation, it was determined that the combined expression of TLN1, APOH, PSMD8, and SYWC can be used as a diagnostic biomarker for distinguishing lung cancer from tuberculosis. HPTR, ANT3, and TLN1 can be used as a biomarker for distinguishing lung cancer from pneumonia. Our results provide a scientific basis for the use of exosomal proteins as biomarkers for the precise identification of lung cancer, tuberculosis, and pneumonia.
[0007] In order to achieve the above object, the present invention provides the following technical solutions:
[0008] 1. The present invention provides an application of pleural effusion exosome protein in the preparation of a product for distinguishing lung cancer from tuberculosis or distinguishing lung cancer from pneumonia; the pleural effusion exosome protein includes TLN1.
[0009] Preferably, the pleural effusion exosome proteins include TLN1 and SYWC.
[0010] Preferably, the pleural effusion exosome proteins include TLN1, SYWC and APOH.
[0011] Preferably, the pleural effusion exosome proteins include TLN1, SYWC, APOH and PSMD8.
[0012] Preferably, the lung cancer is lung cancer with CEA lower than 15 ng / mL.
[0013] Preferably, the product is a detection reagent, a kit, a microarray or a biochip.
[0014] 2. The present invention also provides the use of pleural effusion exosome proteins in the preparation of products for distinguishing pneumonia from pulmonary tuberculosis or distinguishing lung cancer from pulmonary tuberculosis; the pleural effusion exosome proteins include SYWC.
[0015] Preferably, the pleural effusion exosome proteins include SYWC and HV348.
[0016] Preferably, the pleural effusion exosome proteins include SYWC and PSB4.
[0017] Preferably, the pleural effusion exosome proteins include SYWC and PSB9.
[0018] Preferably, the product is a detection reagent, a kit, a microarray or a biochip.
[0019] 3. The present invention also provides the use of pleural effusion exosome proteins in the preparation of products for distinguishing lung cancer from pneumonia; the pleural effusion exosome proteins include ANT3.
[0020] Preferably, the pleural effusion exosome proteins include ANT3 and TLN1.
[0021] Preferably, the pleural effusion exosome proteins include ANT3, TLN1 and HPTR.
[0022] Preferably, the lung cancer is lung cancer with CEA lower than 15 ng / mL.
[0023] Preferably, the product is a detection reagent, a kit, a microarray or a biochip.
[0024] 4. The present invention also provides the use of pleural effusion exosome protein in the preparation of a product for distinguishing pneumonia from tuberculosis; the pleural effusion exosome protein includes HV348.
[0025] Preferably, the product is a detection reagent, a kit, a microarray or a biochip.
[0026] Preferably, the pleural effusion exosome proteins include HV348 and PSB4.
[0027] Preferably, the pleural effusion exosome proteins include HV348 and PSB9.
[0028] 5. The present invention also provides the use of pleural effusion exosome proteins in the preparation of products for distinguishing pneumonia from tuberculosis; the pleural effusion exosome proteins include PSB4 and / or PSB9.
[0029] Preferably, the pleural effusion exosome proteins include HV348, PSB4, and PSB9.
[0030] Compared with the prior art, the present invention has the following beneficial effects:
[0031] The present invention uses multiple cohort samples, one for the discovery cohort and the internal validation cohort, and the other two for independent validation cohorts. Combined with DIA, PRM and ELISA methods, multiple biomarkers such as TLN1, HV348, SYWC, ANT3, PSB4, PSB9 were finally identified, which have important diagnostic value in the differential diagnosis of lung cancer, tuberculosis and pneumonia, and are expected to become new biomarkers for the specific diagnosis of lung cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 This is the experimental design and workflow diagram.
[0033] Figure 2 The following is a description of the phenotypic characteristics of pleural effusion exosomes. (A) CT scan results of patients (the arrow points to pleural effusion, and it is impossible to determine which disease it is from the CT results). (B) Transmission electron microscopy (TEA) analysis of exosomes. Scale bar = 200nm. Representative exosomes are indicated by arrows. (C) Nanoparticle tracking (NTA) analysis of exosomes. (D) Detection and analysis of exosome biomarkers CD9, CD63 and CD81. For the analysis results of CT scans, TEA and NTA, and immunoblotting of biomarkers, only one or several test results are randomly given for each disease. The test results of other patients can be found in the table below. Fig. 9 AC and Fig.10 AB.
[0034] Figure 3 The results of protein expression difference identification for each disease group. (A) Correlation analysis was used to verify the uniformity of the samples. (B) Orthogonal partial least squares discriminant analysis results of pleural effusion exosome proteome. (C) Volcano plot showing differentially expressed proteins between lung cancer group and tuberculosis group. (D) Volcano plot showing differentially expressed proteins between lung cancer group and pneumonia group. (E) Volcano plot showing differentially expressed proteins between tuberculosis group and pneumonia group. (F) Intersection diagram of differentially expressed proteins in three groups.
[0035] Figure 4 Figure 2 shows the results of bioinformatics analysis of differentially expressed proteins. (A) GO enrichment analysis of differentially expressed proteins. The 20 most enriched terms in biological process, cellular component, and molecular function are listed. (B) KEGG pathway analysis of differentially expressed proteins. All enriched pathways are listed. (C) Protein-protein interaction (PPI) network analysis of differentially expressed proteins.
[0036] Figure 5The following are the screening results of candidate biomarkers. (AC) ROC curve analysis of candidate biomarkers for lung cancer and tuberculosis, lung cancer and pneumonia, and tuberculosis and pneumonia. (DF) Hierarchical cluster analysis of three differential diagnosis groups: lung cancer and tuberculosis, lung cancer and pneumonia, and tuberculosis and pneumonia. (G) Correlation analysis between candidate biomarkers and clinical indicators. (HI) Performance of candidate biomarkers in differential diagnosis of lung cancer patients and tuberculosis patients (H) or pneumonia patients (I) with CEA less than or greater than 15 ng / mL in pleural effusion.
[0037] Figure 6 Figures 1 and 2 show the PRM validation results of candidate biomarkers. (AB) Performance of candidate markers in the differential diagnosis of lung cancer patients from patients with pulmonary tuberculosis (A) or patients with pneumonia (B) in the PRM method validation. (C) Performance of candidate markers in the differential diagnosis of patients with pulmonary tuberculosis and patients with pneumonia.
[0038] Figure 7 Figures show the results of ELISA validation and the clinical value evaluation of candidate biomarkers. (AB) Performance of candidate markers in the differential diagnosis of lung cancer patients from patients with pulmonary tuberculosis (A) or patients with pneumonia (B) in ELISA method validation. (C) Performance of candidate markers in the differential diagnosis of patients with pulmonary tuberculosis and patients with pneumonia. (DF) ROC analysis of combined biomarkers for lung cancer and pulmonary tuberculosis (DE), lung cancer and pneumonia (F).
[0039] Figure 8 The following are the results of ELISA validation of independent samples and the results of clinical value evaluation of candidate biomarkers. For specific results and experimental design, please refer to Figure 7 Caption.
[0040] Fig. 9 Figure 1 shows the phenotypic characteristics of pleural effusion exosomes. (A) CT scan of a pleural effusion patient. (B) Transmission electron microscopy analysis of exosomes. Scale bar = 200 nm. Representative exosomes are indicated by arrows. (C) Nanoparticle tracking analysis of exosomes.
[0041] Fig.10 The original images of the immunoblot analysis results for all samples. (A) Figure 2 All original images of D. (B) Provides original images of all discovery cohort samples.
[0042] Fig.11Quality control for DIA proteomics analysis. (A) The total ion chromatogram (TIC) is evenly distributed within the gradient range, and the peak time is relatively stable. (B) The full width at half maximum (FWHM) is around 0.2, indicating that the column performance is stable. (C) iRT elution time diagram between two DIAs. The main iRT retention time was detected to be basically stable. (D) The quantified protein abundance can span 10 orders of magnitude, indicating that the detection depth is very high. (E) The original response value of each sample. (F) The response value of the sample after normalization.
[0043] Fig.12 Figure 2 is the GSEA analysis result of differentially expressed proteins.
[0044] Fig.13 The following are the results of the screening of candidate biomarkers. (A) The performance of candidate markers in the differential diagnosis of patients with tuberculosis and pneumonia. (BE) ROC analysis of the combined biomarkers of lung cancer and tuberculosis (BC) and lung cancer and pneumonia (DE) was performed. DETAILED DESCRIPTION
[0045] The present invention is further described below in conjunction with the accompanying drawings and specific implementation methods. It should be noted that, under the premise of no conflict, the various embodiments or technical features described below can be arbitrarily combined to form a new embodiment.
[0046] Example 1 Screening for candidate biomarkers
[0047] Materials and Methods
[0048] Cohort overview and sample selection
[0049] Methods: PE was collected from patients with lung cancer, tuberculosis, and pneumonia in the Department of Respiratory Medicine of the First Affiliated Hospital of Jinan University and Shunde Hospital Affiliated to Jinan University from January 2014 to December 2023. Patients diagnosed with PE by chest CT underwent pleural puncture, and PE was studied by biochemical, cytopathological, and cell culture methods. PE samples were also systematically divided into lung cancer, pneumonia, and tuberculosis groups. Patient data included: age, sex, tumor history, imaging diagnostic examinations (X-ray, CT, PET), cytopathology, and / or histopathology data at the time of evaluation. Cytopathological analysis was performed under conventional microscopy, and the results were reported in accordance with the International Sebaceous Tumor Reporting System. This study was approved by the Ethics Committee of the First Affiliated Hospital of Jinan University and conducted in accordance with the Declaration of Helsinki.
[0050] Clinical samples
[0051] Detailed information of PE patients who met the inclusion criteria, including demographics, comorbidities, and medications, is shown in Table 1 .
[0052] Table 1 Clinical variables and demographic characteristics
[0053]
[0054] Data are expressed as mean ± SEM (*), number (number), and ratio percentage (%). CEA, carcinoembryonic antigen; ADA, adenosine deaminase; LDH, lactate dehydrogenase; CA199, carbohydrate antigen 19-9; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NLR, neutrophil / lymphocyte ratio.
[0055] Isolation and purification of exosomes
[0056] Pleural effusion specimens were collected and exosomes were isolated and purified. Differential centrifugation was performed at 300 g, 4°C, 10 min, and 10,000 g, 4°C, 60 min to remove floating cells and debris. The supernatant was filtered using a 0.22 μm filter (Merck, SLGVR33RB, USA). The filtered supernatant was ultracentrifuged at 120,000 g for 120 min at 4°C. The supernatant was completely removed and the pellet was resuspended in 10 ml Dulbecco's phosphate-buffered saline (DPBS) (HyClone, SH30028.01, USA) and ultracentrifuged at 120,000 g for 120 min at 4°C. After centrifugation, the supernatant was carefully removed and 100 μL DPBS was gently added to resuspend the exosome pellet.
[0057] Transmission Electron Microscopy (TEM)
[0058] We observed exosomes using transmission electron microscopy as we described previously with slight modifications. Briefly, 30uL of exosomes were fixed in 2% paraformaldehyde solution (GBCBIO, G0528, China) at room temperature for 30 min. 10μL of fixed exosomes were loaded on formvar / carbon film coated grids (400mesh) and left at room temperature for 2min. The grids were stained with 3% phosphotungstic acid solution (Electron Microscopy Sciences, 26458-02, USA). After the grids were dried at room temperature, they were observed using an H-7650 transmission electron microscope (Hitachi, Tokyo, Japan) at 100kV.
[0059] Nanoparticle Tracking Analysis (NTA)
[0060] Exosome samples were diluted 100-fold with DPBS and then analyzed for concentration and size using a NanoSights 300 analyzer (Malvern, Shanghai, China). The shooting parameters for each sample were as follows: thermostat, on; temperature 22°C; camera height, 13; capture duration, 60 seconds. Microparticle tracking and concentration analysis were performed using NTAv3.2 software (Malvern). The analysis parameters of the software were set as follows: detection threshold: 3; water viscosity: 0.9 cP.
[0061] Protein extraction and immunoblotting
[0062] Protein extraction and immunoblotting (IB) experiments were performed as described previously. Briefly, proteins were extracted from exosomes by SDS lysis buffer (Beyotime, P0013G, China), and then the concentration was determined using a BCA kit (ThermoFisher Scientific, 23227, USA). Proteins were separated by 12% SDS-PAGE gel electrophoresis and then transferred to a PVDF membrane (BIO-RAD, 1620177, USA). The membrane was blocked with 5% skim milk for 1 h, followed by antibody incubation and gel band visualization using ECL reagent (Millipore, P90720, USA). The primary antibodies included CD9 monoclonal antibody (1:1000; Invitrogen, USA, 10626D), CD63 monoclonal antibody (1:1000; Invitrogen, USA, 10628D), and CD81 monoclonal antibody (1:1000; Invitrogen, USA, 10630D). Enzyme-labeled goat anti-mouse IgG (H+L) secondary antibody was purchased from Bioworld (1:4000, Bioworld, BS12478, USA), and enzyme-labeled goat anti-rabbit IgG (H+L) secondary antibody was purchased from Tianjin Sungene Biotechnology Co., Ltd. (Tianjin Sungene, LK2001, China).
[0063] Protein trypsin digestion
[0064] Protein digestion was performed using filter-assisted sample preparation (FASP). In brief, the protein was treated with 8M urea (pH = 8.0, Tris-HCl) to a final concentration of 4M, then reduced with 50mM DTT (Solarbio, D8220, China) in a 37°C water bath for 1 hour, and then alkylated with 100mM IAA (Merck, I6125, USA) for 30 minutes in the dark. Then, the mixed solution was loaded into a 10kDa ultracentrifuge tube (Merck, UFC501096, USA), centrifuged at 12,000g for 15 minutes, the supernatant was removed, and then washed twice with 8M urea, washed 3 times with 50mM TEAB buffer, and centrifuged at 12,000g for 15 minutes. Trypsin (Promega, V5280, USA) was then added at a ratio of 1:40 (W:W, trypsin: protein) and incubated overnight at 37°C. After 12 h, peptides were collected and analyzed using the Pierce Quantitative Fluorescent Peptide Assay Kit (Thermo Scientific TM Finally, all peptides were freeze-dried and stored at -80°C.
[0065] Desalting of peptides
[0066] We used a C18 column to desalt the peptides. The peptides were then dissolved with 200 μL of 0.5% trifluoroacetic acid (TFA) (Macklin, T818782, China) solution and desalted using a MonoTip C18 column (GL Sciences Inc, 1FTD156, Japan) according to the product instructions. All peptides were then freeze-dried and stored at -80°C.
[0067] Data Dependent Acquisition (DDA) and Data Independent Acquisition (DIA) Mass Spectrometry
[0068] Mass spectrometry (MS) data were obtained using nano-uHPLC-MS / MS analysis. First, the peptide was dissolved in solvent A (0.1% formic acid in water, Thermo Scientific TM, A117-50, USA), and analyzed using an Orbitrap FusionLumos mass spectrometer (Thermo Fisher Scientific, USA) and an EASY-nanoLC 1000 system (ThermoFisher Scientific, USA). Briefly, the peptides were loaded onto a chromatographic column (omics high-resolution series monolithic capillary HPLC column, 75 μm × 50 cm, KYOTO MONOTCHE), and eluted with solvent a (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile) for 90 min, with an elution gradient of: 0-3 min, 4-7% B, 3-59 min, 7-20% B, 59-80 min, 20-30% B, 80-82 min, 30-90% B, 82-90 min, 90% B, at a constant flow rate of 600 nL / min. The column temperature was set at 50 °C, and the mass spectrometer electrospray inlet voltage was set at 2.2 kV.
[0069] Data-dependent acquisition (DDA) mass spectrometry was used to establish the spectral library. The parameters of the spectral library were as follows: (1) MS scan: scanning range (m / z): 350-1500; orbital trap resolution: 120,000; AGC target: 4×10 5 ; Maximum injection time: 50ms; RF lens: 45%; (2) MS / MS scanning: orbitrap resolution: 30000; AGC target: 5×10 4 ; HCD collision energy: 32; maximum injection time: 120 ms; isolation window: 1.6 Da; exclusion duration: 30 ms.
[0070] Quantitative proteomics analysis was performed using high-resolution MS1 data-independent acquisition (HRMS1-DIA) mode with the following parameters: (1) MS scan: scan range (m / z): 350–1500; orbitrap resolution: 120,000; AGC target: 4.8 × 10 5 , maximum injection time: 50ms; RF lens: 45%; (2) tMSn scan: track resolution: 30,000; AGC target: 2×10 5 ; HCD collision energy: 32; Maximum injection time: 72ms; Scan window: 20 isolation windows / cycle × 3 cycles.
[0071] Parallel Reaction Monitoring (PRM) Targeted Proteomics
[0072] Unique peptides corresponding to candidate proteins were selected (Supplementary Table 4) and PRM quantification was performed on a Dionex U3000 UPLC-Orbitrap Exploris 480 mass spectrometer system (Thermo Scientific). Briefly, 1 ug of trypsin-digested protein was loaded onto a precolumn (ThermoScientific Acclaim PepMap C18, 100 μm x 2 cm) at a flow rate of 5 μL / min, and then separated on an analytical column (Acclaim PepMap C18, 75 μm x 25 cm) with a 60 min gradient. Mass spectrometry analysis: MS1 scanning range 325-1350 m / z; resolution 60K; AGC target 1×10 6 ; MS2 acquisition used the targeted MS2 module to monitor the target m / z list (Table S1) with a resolution of 30K; the isolation window was 1.6 Da; the AGC target was 1×10 5 ; The maximum injection time was 120ms; The HCD collision energy was 30%; The time window around the expected precursor detection time was kept for 6min. Proteome Discoverer 2.5 (ThermoScientific) was used to search the database of the PRM raw data, and then the MSF file was loaded into Skyline 20.1 (PMID: 28691345), generating peptides with a length of 7 to 30aa, a scoring threshold of 0.05, and ion types of b ions, y ions, and p ions; 3 point p values greater than 0.8 can be used for peptide quantification and protein quantification.
[0073] Database Search
[0074] In order to obtain a precise and comprehensive spectral library, we combined the DDA raw data with the HRMS1-DIA raw data to construct a hybrid library. Briefly, the raw data of DDA and HRMS1-DIA were searched using Spectronaut Pulsar 14.2.200619.47784 (Biognosys, Switzerland) software. The default settings were used: enzyme / cleavage rule: trypsin / P; fixed modification: carbamidomethyl (C); variable modification: oxidation (M); tolerance: 20 ppm; precursor and protein false discovery rate (FDR): 1%.
[0075] Then, the HRMS1-DIA data were analyzed using Spectronaut software with default settings using the hybrid library constructed above as a reference database. The retention time prediction type was set to dynamic iRT, and Spectronaut will dynamically determine the ideal extraction window based on the iRT calibration and gradient stability. The q-values at the precursor and protein levels were set to 1%. All selected precursors passed the filter for MS1 quantification. All interfering peaks in the MS2 spectrum were removed except for the three peaks with the least interference. The first 3 filtered peptides that passed the 1% q-value cutoff were used to calculate the abundance values of the protein. Enzyme-linked immunosorbent assay (ELISA)
[0076] ELISA kits for human serpin1 (antithrombin-III, ANT3), human PSMB9 (proteasome β-9 subunit), human HPR (Haptoglobin-related protein), PSMB4 (proteasome β-4 subunit), human APOL1 (apolipoprotein L1), and human APOH (β-2 glycoprotein 1) were purchased from Wuhan Fine Biotech Co., Ltd (Wuhan, Hubei, China). ELISA kits for human IGKV4-1 (KV401), human IgHV3-7 (HV307), human IGHG2, human Ighv3-48 (HV348), human IGLC7, and human TLN1 (Talin-1) were purchased from Jiangsu Meimian Industrial Co., Ltd (Jiangsu, Nanjing, China). ELISA kits for human WARS (Tryptophanyl tRNA synthetase, SYWC) were purchased from Cloud-Clone (Houston, USA). ELISA for all samples was performed according to the manufacturer's instructions. After the experiment, the optical density (OD) was measured using a full-wavelength enzyme label (BIOTEK, USA), set at 450 nm, and the concentrations of candidate biomarkers in different disease groups were compared. All ELISA kits were standard 96-well or 48-well formats, and sandwich antibody-based ELISAs were designated "for research purposes".
[0077] Bioinformatics and statistical analysis
[0078] Statistical analysis of clinical variables and demographic characteristics of the samples was as follows: discrete data were analyzed using the chi-square test. For continuous data analysis, the comparison between the two groups was performed using the unpaired t-test with Welch's correction, and the comparison between the three groups was performed using the Kruskal-Wallis test. Data were expressed as mean ± SEM. These analyses were performed in GraphPad Prism 6 software.
[0079] To analyze differentially expressed proteins (DEPs), we first used the K-nearestNeighbor (KNN, K=5) method to fill in missing values, then normalized the data using z-score, and then performed statistical analysis using the unpaired t test with Welch's correction. A p value of <0.05 was considered significant. OPLS-DA analysis, gene ontology (GO) enrichment analysis (including cellular component, biological process, and molecular function terms), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, correlation analysis, and cluster analysis were performed using the "Wukong" platform (https: / / www.omicsolution.com / wkomics / main / ). Protein-protein interaction (PPI) analysis was performed by metscape (http: / / metascape.org / gp / index.html# / main / step1). Receiver operating characteristic (ROC) analysis was performed using SPSS statistical software (IBM SPSSstatistics 26). Survival analysis was performed using Kaplan-Meier Plotter (http: / / kmplot.com / analysis / index.php?p=background). GraphPad Prism 6 software and R program were used for plotting.
[0080] result
[0081] PE exosomes from patients with lung cancer (LC), tuberculosis (T), and pneumonia (P)
[0082] The overall strategy of this study is Figure 1 The clinical imaging characteristics (CT scans) of the patients are shown in Figure 2 A and Fig. 9 A. We found that CT scans of patients with lung cancer, tuberculosis, and pneumonia all showed varying degrees of irregular pleural effusions, and the three diseases could not be distinguished based on CT results alone. Through TEM analysis, we observed that the expected size of exosomes isolated from pleural effusions of the three diseases was 70-200nm ( Figure 2 B and Fig. 9 B). Further verification by nanoparticle tracking analysis (NTA) showed that the particle size of most exosomes was less than 200 nm, mainly distributed between 70-130 nm ( Figure 2 C and Fig. 9C). For a small portion of observed particles larger than 200 nm, this may be due to the aggregation of some particles to form aggregates that cannot be distinguished by nanoparticle tracking analysis. However, the size distribution pattern of exosomes detected by NTA is consistent with other reports, indicating that the purity of exosomes separated by PE is acceptable. In addition, we performed Western blotting analysis using exosome markers (CD9, CD63, and CD81) and found that all samples expressed exosome markers CD9, CD63, and CD81 to varying degrees ( Figure 2 D and Fig.10 AB). These results indicate that we have isolated highly purified exosomes from pleural effusions of three diseases.
[0083] Proteomics of PE exosomes in LC, T and P groups
[0084] Data-independent acquisition (DIA) mass spectrometry has been selected as the most noteworthy technology in the next few years due to its high throughput, high precision and high repeatability. The mixed library constructed based on DDA and DIA data and used for DIA quantitative proteomics analysis is even more beneficial for proteomics analysis. Therefore, we next used the mixed library for DIA-based quantitative proteomics analysis to identify differentially expressed exosomal proteins. To evaluate the quality of mass spectrometry data, we used total ion chromatogram (TIC) and full width at half maximum (FWHM) to evaluate the performance of the chromatographic column, and used standard peptide iRT to evaluate the stability of each sample. We found that the TIC in all samples was evenly distributed within the gradient range, and the peak time was relatively stable ( Fig.11 A). In addition, the FWHM of each peptide is approximately 0.3 ( Fig.11 B). These results indicate that the column is stable. When the standard peptide iRT was used as calibration for DIA data acquisition, the results showed that the iRT peptide was stable in all samples ( Fig.11 C), indicating good quantification accuracy of proteins in our samples. When we checked the quantification depth of proteins (Ranked protein groups (RPGs)), we found that RPGs can span 10 orders of magnitude, indicating that we can also identify low-abundance proteins ( Fig.11 D). After normalization, the original responses of all samples also show good results ( Fig.11 EF). The above results indicate that the quality of our proteomics data is acceptable.
[0085] Next, we performed correlation analysis on the proteomic data of all samples. The results showed that the correlation coefficients of the lung cancer group, tuberculosis group, and pneumonia group samples were R = 0.5677-0.8766, R = 0.6823-0.8820, and R = 0.4945-0.8403 ( Figure 3 A). This result indicates that in our sample, the differences between individuals within the group are small and the sample distribution is uniform. Orthogonal partial least squares discriminant analysis (OPLS-DA) analysis showed that the sample distribution within the LC group, T group, and P group was relatively concentrated, but the distributions between the three groups were almost completely separated ( Figure 3 B), indicating that our proteomic data can well distinguish the three diseases. This not only reflects the specificity of each disease, but also shows the accuracy of our sample diagnosis. The above results show that our proteomic data can well distinguish the three groups of pleural effusion. Therefore, we then analyzed the differentially expressed proteins between the three groups. The volcano plot showed that compared with the T group, the LC group had 109 differentially expressed proteins (DEPs), of which 99 were upregulated and 10 were downregulated. Compared with the P group, the LC group had 109 DEPs, of which 107 proteins were upregulated and 2 proteins were downregulated. Compared with the P group, the T group had 49 DEPS, of which 42 proteins were upregulated and 7 proteins were downregulated ( Figure 3 CE). We observed that most DEPs in the LC group were upregulated compared with those in the T and P groups, which may be related to more active protein translation in tumors
[41] . In addition, our results showed that the DEPs in the LC group were also greater than those in the T and P groups ( Figure 3 F), indicating that lung cancer is a disease that is very different from tuberculosis and pneumonia. In conclusion, our results suggest that it is possible to identify suitable diagnostic biomarkers to distinguish lung cancer, tuberculosis, and pneumonia in our study cohort. Functional analysis of differentially expressed proteins (DEPs)
[0086] Subsequently, we performed gene ontology (GO) cellular component (CC) analysis on the differentially expressed proteins (DEPs), and the results showed that the top three DEPs were extracellular proteins, such as extracellular exosomes, extracellular regions, and extracellular spaces ( Figure 4 A), which is consistent with the characteristics of our sample type (i.e., exosomes). The results of biological process (BP) analysis showed that compared with the tuberculosis and pneumonia groups, DEPs in the lung cancer group were mainly involved in biological processes such as platelet degranulation, coagulation, lipoprotein and retinoid metabolism, and extracellular matrix organization. Compared with the pneumonia group, DEPs in the tuberculosis group were mainly involved in biological processes such as Fc-epsilon receptor signaling pathway, mRNA stability regulation, MAPK cascade, protein polyubiquitination, and stimulation of C-type lectin receptor signaling pathway ( Figure 4A). The results of molecular function analysis showed that in the lung cancer group, compared with the tuberculosis group and the pneumonia group, the top three GO terms enriched in DEPs were calcium ion binding, serine endopeptidase inhibitor activity, and heparin binding. Compared with the pneumonia group, the top three DEPs in the tuberculosis group were threonine endopeptidase activity, serine endopeptidase activity, and antigen binding ( Figure 4 A).
[0087] Then, we also performed KEGG pathway analysis and found that the differentially expressed proteins were mainly enriched in the complement and coagulation cascades, cholesterol metabolism, and proteasome pathways ( Figure 4 B). In addition, protein-protein interaction (PPI) analysis also showed that DEPs mostly formed tight protein interaction networks in platelet degranulation, proteasome, complement activation, and lipoprotein metabolism ( Figure 4 C). Gene set enrichment analysis (GSEA) also showed that most DEPs were enriched in cellular metabolic processes ( Fig.12 AC) and proteasome ( Fig.12 D).
[0088] In summary, the results of GO, KEGG and PPI analysis suggest that complement activation, proteasome, platelet degranulation and cell metabolism processes may be closely related to the nature of lung cancer, tuberculosis and pneumonia. Therefore, we will further screen candidate markers based on the DEPs of the above four pathways.
[0089] Identification of candidate biomarkers
[0090] Based on the functional analysis results, we conducted a literature survey on DEPs in the four key pathways and selected DEPs that have not been reported in lung cancer, tuberculosis, and pneumonia as candidate biomarkers. 28 candidate biomarkers were selected for further evaluation. We then performed receiver operating characteristic (ROC) analysis on these 28 candidate markers to evaluate their diagnostic accuracy and selected candidate biomarkers with an AUC of 0.70 or above in each group. We found that a total of 18 candidate biomarkers with an AUC score higher than 0.7 had good clinical value. The detailed information of the 18 candidate biomarkers is shown in Table 2, and the detailed ROC analysis results are shown in Figure 5 AC. Hierarchical cluster analysis (HCA) showed that the combination of the three markers had a good differential diagnosis effect ( Figure 5 DF). Interestingly, we conducted a correlation analysis between these 18 candidate markers and routine clinical examination indicators. The results showed that except for IGHG2, which was positively correlated with age, IGHG4 and APOH, which were negatively correlated with LDH, and TLN1, which was negatively correlated with ADA, most of the candidate markers had no correlation with clinical examination indicators ( Figure 5G). These results suggest that our candidate markers can be used for the differential diagnosis of these three diseases without interference from clinical markers.
[0091] It is well known that the carcinoembryonic antigen (CEA) index in PE is a biomarker for cancer. In general, CEA in PE of lung cancer patients is generally higher than 15ng / mL. However, excitingly, our results show that when the tumor marker CEA in PE of lung cancer patients is lower than 15ng / mL, these candidate markers still have advantages. We found that the candidate markers TLN1, APOH, PSMD8, and SYWC can not only distinguish lung cancer from tuberculosis well, but also distinguish lung cancer patients with CEA lower than 15ng / mL from tuberculosis patients ( Figure 5 H). Similarly, the three candidate markers HPTR, ANT3, and TLN1 can also well distinguish lung cancer patients and pneumonia patients whose CEA in pleural fluid is less than 15 ng / mL ( Figure 5 I). In addition, the detection of adenosine deaminase (ADA) in pleural effusion is also of great clinical significance in assisting the diagnosis of pulmonary tuberculosis. Clinically, the ADA in the pleural effusion of patients with pulmonary tuberculosis is generally higher than 45U / L. However, in our study, it was found that many patients with pneumonia had higher ADA levels (average 45.60±15.88), which was not statistically significant compared with patients with pulmonary tuberculosis (p=0.8335) (Table 1). At this time, pulmonary tuberculosis is difficult to distinguish from pneumonia. Interestingly, we found that 10 candidate markers, including PSB9 and PSB4, performed well in the differential diagnosis of pulmonary tuberculosis and pneumonia, even though there was no difference in ADA in the pleural effusion between patients with pneumonia and patients with pulmonary tuberculosis ( Fig.13 A). It is noteworthy that TLN1 is highly expressed in lung cancer, while SYWC is specifically highly expressed in pulmonary tuberculosis, suggesting that TLN1 and SYWC may be specific diagnostic markers for lung cancer and pulmonary tuberculosis, respectively.
[0092] We also found that in the ROC analysis of lung cancer and tuberculosis, when TLN1, APOH, PSMD8, and SYWC were used together, the AUC, sensitivity, and specificity scores were greatly improved, and the specificity even reached 100% ( Fig.13 B). Even in lung cancer with CEA lower than 15 ng / ml, compared with pulmonary tuberculosis, when 4 subjects were used together, the AUC score was 1.00, and the sensitivity and specificity scores were both 100% ( Fig.13 C, in the differential analysis between lung cancer and pneumonia, and between lung cancer with CEA below 15 ng / ml and pneumothorax, when HPTR, ANT3, and TLN1 were used together, the AUC, sensitivity, and specificity scores were also greatly improved ( Fig.13DE). These results suggest that the combination of TLN1, APOH, PSMD8, and SYWC or the combination of HPTR, ANT3, and TLN1 can serve as biomarkers for the differential diagnosis of lung cancer and tuberculous pleural effusion, and lung cancer and pneumonic pleural effusion, respectively.
[0093] In summary, our results showed that these candidate biomarkers, TLN1, APOH, PSMD8, SYWC, HPTR, HV348, ANT3, PSB9, and PSB4, had important diagnostic value in the differential diagnosis of lung cancer, tuberculosis, and pneumonic pleural effusion.
[0094] Example 2 Validation and Evaluation of Candidate Biomarkers
[0095] Parallel Reaction Monitoring (PRM) Validation of Candidate Biomarkers
[0096] Parallel Reaction Monitoring (PRM) analysis is a targeted quantitative technology based on high-resolution, high-precision, and high-accuracy mass spectrometry to achieve absolute or relative quantitative analysis of target proteins or peptides. Therefore, we subsequently used the PRM method to validate the 18 candidate biomarkers selected above in an internal cohort (Table 2). Our results found that the four candidate biomarkers, APOH, SYWC, IPSP, and ANT3, had good consistency between DIA and PRM results in the lung cancer, tuberculosis, and pneumonia groups, indicating that our test results were reliable ( Figure 6 AC). For the remaining 14 candidate biomarkers, although their quantitative trends were consistent with the DIA results, they were not statistically conclusive. This may be due to methodological limitations of targeted proteomics methods such as PMR and dynamic suppression of multiple reaction monitoring (MRM). At the same time, it also illustrates the huge differences between clinical samples and highlights the challenges faced by current biomarker validation.
[0097] Table 2. Biological information of the 18 candidate proteins identified
[0098]
[0099]
[0100] ELISA validation and evaluation of candidate biomarkers
[0101] To further validate our candidate markers and prepare for further use in clinical trials, we further expanded the sample cohort size and used ELISA to validate and evaluate the clinical value of candidate markers with consistent expression trends in DIA and PRM methods. Our results showed that the quantitative trends of the four candidate marker proteins, TLN1, APOH, SYWC, and ANT3, were consistent with the results of DIA and PRM, and the differences among the three groups were statistically significant ( Figure 7 AC).
[0102] We then used ROC analysis to evaluate the efficacy of candidate biomarkers. We found that compared with lung cancer and tuberculosis, the AUC scores of TLN1, APOH, and SYWC alone ranged from 0.686 to 0.929, and the sensitivity and specificity ranged from 60% to 95%, which had good clinical value. However, when TLN1, APOH, and SYWC were used in combination, the AUC, sensitivity, and specificity scores were greatly improved ( Figure 7 D). These results suggest that the combination of TLN1, APOH, and SYWC can be used as a differential diagnostic biomarker for lung cancer and tuberculous pleural effusion. In the lung cancer analysis, the sensitivity of TLN1 and ANT3 alone was slightly lower than that of the pneumonia analysis, but still had good AUC and specificity. When the two subjects were used in combination, the AUC score was 0.944 and the sensitivity score was 97.80%, which was a good clinical evaluation ( Figure 7 E). These results suggest that the combination of TLN1 and ANT3 can be used as a biomarker for the differential diagnosis of lung cancer and pneumonic pleural effusion. In the comparison between tuberculosis and pneumonia, SYWC showed excellent AUC, sensitivity, and specificity, with a score of 100% ( Figure 7 F). This indicates that SYWC is a specific diagnostic biomarker for pulmonary tuberculosis.
[0103] Next, for further validation, we used samples that were independent (completely different) from the proteomics screening and performed ELISA validation again, including validation of sensitivity and specificity of individual proteins and combined use. The method used was the same as the previous method, see Figure 8 The results are similar to those mentioned above. Figure 7 and Fig.13 The verification results are consistent.
[0104] In ROC analysis, the value corresponding to the Youden index is the specific threshold for diagnostic judgment, which is:
[0105] In the differential diagnosis of lung cancer and tuberculous pleural effusion: the threshold value of TLN1 is 24.2819ug / ml, and a value higher than this value can theoretically be diagnosed as lung cancer; the threshold value of SYWC is 15.3163ng / ml, and a value higher than this value can theoretically be diagnosed as tuberculosis.
[0106] In the differential diagnosis of lung cancer and pneumonic pleural effusion: the threshold value of TLN1 is 25.5038ug / ml, and a value higher than this value can theoretically be diagnosed as lung cancer; the threshold value of ANT3 is 9.6574ug / ml, and a value higher than this value can theoretically be diagnosed as lung cancer.
[0107] In the differential diagnosis of tuberculosis and pneumonia: the threshold of SYWC is 15.2165ng / ml, and a value higher than this can theoretically be diagnosed as tuberculosis; the threshold of HV348 is 2.0506ng / ml, and a value higher than this can theoretically be diagnosed as tuberculosis. The threshold of PSB4 is 18.4398ng / ml, and a value higher than this can theoretically be diagnosed as tuberculosis; the threshold of PSB9 is 17.4791ng / ml, and a value higher than this can theoretically be diagnosed as tuberculosis.
[0108] In summary, we used at least three cohort samples, one for the discovery cohort and the internal validation cohort, and the other two for independent validation cohorts, and combined DIA, PRM, and ELISA methods to finally identify multiple biomarkers such as TLN1, HV348, SYWC, ANT3, PSB4, PSB9, etc., which have important diagnostic value in the differential diagnosis of lung cancer, tuberculosis, and pneumonia, and are expected to become potential biomarkers for differentiating pleural effusion caused by lung cancer, tuberculosis, and pneumonia.
[0109] The above-mentioned embodiments are only preferred embodiments of the present invention and cannot be used to limit the scope of protection of the present invention. Any non-substantial changes and substitutions made by technicians in this field on the basis of the present invention shall fall within the scope of protection required by the present invention.
Claims
1. Application of pleural effusion exosome protein in the preparation of a product for distinguishing pneumonia from tuberculosis; characterized in that: The pleural effusion exosome proteins include HV348.
2. The use according to claim 1, characterized in that: The product is a detection reagent, a test kit, a microarray or a biochip.
3. The use according to claim 1, characterized in that: The pleural effusion exosome proteins include HV348 and PSB4.
4. The use according to claim 1, characterized in that: The pleural effusion exosome proteins include HV348 and PSB9.
5. Application of pleural effusion exosome protein in the preparation of a product for distinguishing pneumonia from tuberculosis; characterized in that: The pleural effusion exosome proteins include PSB4 and / or PSB9.
6. The use according to any one of claims 1 to 5, characterized in that: The pleural effusion exosome proteins include HV348, PSB4, and PSB9.
